Loading stock data…
ROCHE PS (ROP.SW)
CHF 338.80+2.80 (+0.83%)
Market ClosedLast close Jun 29
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Roche Holding AG in the Healthcare sector is trading at $338.80 with a market capitalization of $269.6B. Wall Street consensus targets $358.83 (18 analysts), implying a +5.9% move over the next 12 months. The stock is currently 10% below its 52-week high of $374.90, remaining 9.5% above its 200-day moving average. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +5.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Annual Financials
| Metric (CHF) · Annual | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Total Revenue | CHF 65.81B↑ | CHF 60.44B↓ | CHF 62.40B↓ | CHF 63.36B |
| Gross Profit | CHF 46.08B↑ | CHF 44.08B↓ | CHF 46.11B↓ | CHF 46.71B |
| Operating Income | CHF 17.48B↑ | CHF 15.39B↑ | CHF 13.42B↓ | CHF 18.48B |
| Net Income | CHF 12.42B↑ | CHF 11.50B↑ | CHF 8.28B↓ | CHF 12.88B |
Peer Comparison
JNJUNHPFE
Fundamentals
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tum...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
CHF 269.56B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
21.14
Beta
Defensive asset. Lower volatility than the S&P 500.
0.33
Div Yield
Strong income play. Yield provides a meaningful total return floor.
292.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
37.27%
Volume
Today's trading volume
738,101
Recent News
3 late-stage MASH drugs that could rival Rezdiffra
The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.
Nurix Stock Up 29% in a Month: Here's What You Should Know
NRIX rallies on its collaboration with Roche for bexobrutideg, featuring a $700 million upfront payment and potential milestone payouts of up to $2.3 billion.
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Nurix (NRIX) Climbs to 52-Week High — This Deal May Hold the Answer
Nurix Therapeutics Inc. (NASDAQ:NRIX) is one of the 9 Stocks Winning by Double Digits. Nurix Therapeutics extended its gains to an 8th straight session on Thursday, touching a new 52-week high, as investors resumed buying positions following an earlier partnership with Roche for the co-development of a blood cancer treatment. In intra-day trading, the stock […]
VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development
By Daniella Parra VERAXA Biotech AG (Nasdaq: VRXA)has expanded its R&D facility in Heidelberg, Germany, increasing laboratory space by more than 60% to support team growth and accelerate its cancer therapy programs toward clinical development, the company said. The expansion strengthens research capabilities while allowing the company to remain in Heidelberg’s leading medical oncology hub […] The post VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development a